(NASDAQ: BVS) Bioventus's forecast annual revenue growth rate of 5.98% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.24%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Bioventus's revenue in 2026 is $581,848,000.On average, 6 Wall Street analysts forecast BVS's revenue for 2026 to be $51,365,843,060, with the lowest BVS revenue forecast at $49,611,686,444, and the highest BVS revenue forecast at $53,507,663,244. On average, 6 Wall Street analysts forecast BVS's revenue for 2027 to be $54,831,269,435, with the lowest BVS revenue forecast at $52,824,837,178, and the highest BVS revenue forecast at $57,922,486,944.
In 2028, BVS is forecast to generate $58,226,899,550 in revenue, with the lowest revenue forecast at $56,409,674,023 and the highest revenue forecast at $60,720,223,792.